Treatment of CNS diseases with sGC stimulators
AssigneeCyclerion Therapeutics, Inc.
InventorsJoon Jung, Thomas Wai-Ho Lee, Rajesh R. Iyengar, Nicholas Robert Perl, Peter Germano, Maria D. Ribadeneira, Kim Tang
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3′,5′-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.
Claims2
A method of enhancing memory or reversing memory disruption or impairment in a subject in need thereof, comprising administering, alone or in combination therapy, a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof to the subject in need thereof, wherein the compound is selected from those depicted in Table I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or a dosage form comprising said compound or pharmaceutically acceptable salt thereof:
- TABLE I
- Compound
- Structure
- Number
- I-5
- I-2.
A method of improving or restoring synaptic transmission and neuronal plasticity, or improving long term potentiation in a subject in need thereof, comprising administering, alone or in combination therapy, a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof to the subject in need thereof, wherein the compound is selected from those depicted in Table I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or a dosage form comprising said compound or pharmaceutically acceptable salt thereof:
- TABLE I
- Compound
- Structure
- Number
- I-5
- I-2.
Dependencies are inferred from the claim text.